Onconetix, Inc.(ONCO)Earnings, Financials & Key Ratios
ONCO•NASDAQ
$0.45
$2M mkt cap·Price updated May 6, 2026
AboutOnconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Show more
- Revenue$815K-67.7%
- EBITDA-$6M+88.6%
- Net Income-$14M+76.1%
- EPS (Diluted)-4.73+99.1%
- Gross Margin77.62%+85.7%
- EBITDA Margin-776.3%+64.9%
- Operating Margin-778.16%+65.2%
- Net Margin-1720.98%+26.0%
- ROE-110.6%+89.6%
- ROIC-32.81%+90.3%
- Debt/Equity0.00-99.7%
- Interest Coverage-8.45+79.6%
ONCO Key Insights
Onconetix, Inc. (ONCO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Profits declining 54.4% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ONCO Price & Volume
Onconetix, Inc. (ONCO) stock price & volume — 10-year historical chart
Loading chart...
ONCO Growth Metrics
Onconetix, Inc. (ONCO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-67.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM76.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-8335.29%
Return on Capital
10 Years-76.62%
5 Years-98.3%
3 Years-89.33%
Last Year-49.41%
ONCO Peer Comparison
Onconetix, Inc. (ONCO) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRVS | 1.15B | 15.45 | -29.15 | -23.29% | 0.02 | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 JANX | 882.82M | 14.62 | -7.99 | -5.55% | -8.82% | -16.48% | 0.02 | |
 ARCC | 13.76B | 19.16 | 10.30 | 32.87% | 8.11% | 1.12 | ||
 ORIC | 962.71M | 9.30 | -6.33 | -35.33% | 0.03 |
Compare ONCO vs Peers
Onconetix, Inc. (ONCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ONCO Income Statement
Onconetix, Inc. (ONCO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 58.47K | 2.52M | 815.37K |
| Revenue Growth % | - | - | - | - | - | 4217.31% | -67.7% |
| Cost of Goods Sold | 573 | 3.06K | 4.89K | 6.75K | 1.19M | 1.47M | 182.46K |
| COGS % of Revenue | - | - | - | - | 2027.93% | 58.2% | 22.38% |
| Gross Profit | -573▲ 0% | -3.06K▼ 433.3% | -4.89K▼ 60.0% | -6.75K▼ 38.1% | -1.13M▼ 16593.8% | 1.06M▲ 193.6% | 632.91K▼ 40.0% |
| Gross Margin % | - | - | - | - | -1927.93% | 41.8% | 77.62% |
| Gross Profit Growth % | - | -433.33% | -60.01% | -38.08% | -16593.79% | 193.61% | -40.01% |
| Operating Expenses | 879.66K | 1.62M | 3.42M | 13.48M | 34.91M | 57.54M | 6.98M |
| OpEx % of Revenue | - | - | - | - | 59706.54% | 2279.76% | 855.78% |
| Selling, General & Admin | 819.49K | 1.1M | 2.09M | 9.35M | 14.77M | 11.23M | 7.04M |
| SG&A % of Revenue | - | - | - | - | 25264.14% | 444.99% | 863.89% |
| Research & Development | 60.17K | 524.91K | 1.33M | 4.13M | 1.95M | 154.36K | 66.13K |
| R&D % of Revenue | - | - | - | - | 3334.31% | 6.12% | 8.11% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 18.19M | 46.16M | -132.27K |
| Operating Income | -880.23K▲ 0% | -1.62M▼ 84.3% | -3.42M▼ 110.7% | -13.48M▼ 294.5% | -36.03M▼ 167.3% | -56.49M▼ 56.8% | -6.34M▲ 88.8% |
| Operating Margin % | - | - | - | - | -61634.47% | -2237.96% | -778.16% |
| Operating Income Growth % | - | -84.28% | -110.68% | -294.5% | -167.29% | -56.76% | 88.77% |
| EBITDA | -879.66K | -1.62M | -3.41M | -13.47M | -35.99M | -55.76M | -6.33M |
| EBITDA Margin % | - | - | - | - | -61559.32% | -2208.99% | -776.3% |
| EBITDA Growth % | - | -84.05% | -110.77% | -294.86% | -167.1% | -54.92% | 88.65% |
| D&A (Non-Cash Add-back) | 573 | 3.06K | 4.89K | 6.75K | 43.94K | 731.35K | 15.17K |
| EBIT | -821.91K | -1.6M | -3.42M | -13.42M | -36.75M | -58.33M | -6.34M |
| Net Interest Income | 58.32K | 22.6K | 0 | 0 | -671.63K | -1.41M | -751K |
| Interest Income | 58.32K | 22.6K | 0 | 0 | 0 | 18 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 671.63K | 1.41M | 751K |
| Other Income/Expense | 58.32K | 22.6K | 0 | 61.41K | -1.39M | -3.25M | -7.69M |
| Pretax Income | -821.91K▲ 0% | -1.6M▼ 94.6% | -3.42M▼ 113.7% | -13.42M▼ 292.7% | -37.42M▼ 178.9% | -59.74M▼ 59.6% | -14.03M▲ 76.5% |
| Pretax Margin % | - | - | - | - | -64008.02% | -2366.62% | -1720.91% |
| Income Tax | 0 | 0 | 0 | 0 | -12.59K | -1.05M | 525 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0.03% | 1.75% | -0% |
| Net Income | -821.91K▲ 0% | -1.6M▼ 94.6% | -3.42M▼ 113.7% | -13.42M▼ 292.7% | -37.41M▼ 178.8% | -58.69M▼ 56.9% | -14.03M▲ 76.1% |
| Net Margin % | - | - | - | - | -63986.48% | -2325.21% | -1720.98% |
| Net Income Growth % | - | -94.6% | -113.65% | -292.7% | -178.76% | -56.89% | 76.09% |
| Net Income (Continuing) | -821.91K | -1.6M | -3.42M | -13.42M | -37.41M | -58.69M | -14.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 7.01M | 0 | 0 |
| EPS (Diluted) | -0.02▲ 0% | -0.04▼ 87.8% | -0.09▼ 121.5% | -0.31▼ 251.5% | -25.03▼ 7937.4% | -520.93▼ 1981.3% | -4.73▲ 99.1% |
| EPS Growth % | - | -88.17% | -121.43% | -251.61% | -7936.7% | -1981.34% | 99.09% |
| EPS (Basic) | -0.02 | -0.04 | -0.09 | -0.31 | -25.03 | -520.93 | -4.73 |
| Diluted Shares Outstanding | 11.37K | 11.37K | 11.37K | 12.63K | 17.61K | 113.05K | 3.28M |
| Basic Shares Outstanding | 11.37K | 11.37K | 11.37K | 12.63K | 17.61K | 113.05K | 3.28M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
ONCO Balance Sheet
Onconetix, Inc. (ONCO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 6.06M | 4.6M | 3.07M | 26.26M | 5.84M | 950.27K | 6.07M |
| Cash & Short-Term Investments | 6.05M | 4.31M | 1.93M | 25.75M | 4.55M | 646.5K | 5.22M |
| Cash Only | 6.05M | 4.31M | 1.93M | 25.75M | 4.55M | 646.5K | 5.22M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.33K | 44.8K | 152.52K | 35.85K | 149.73K | 96.31K | 296.87K |
| Days Sales Outstanding | - | - | - | - | 934.78 | 13.93 | 132.89 |
| Inventory | 0 | 0 | 0 | 0 | 364.05K | 64.08K | 149.96K |
| Days Inventory Outstanding | - | - | - | - | 112.07 | 15.92 | 299.99 |
| Other Current Assets | 0 | 0 | 757.65K | 0 | 0 | 0 | 92K |
| Total Non-Current Assets | 21.93K | 215.6K | 11.5K | 52.71K | 81.68M | 27.23M | 18.86M |
| Property, Plant & Equipment | 6.93K | 15.67K | 11.5K | 14.09K | 209.2K | 182.32K | 85.86K |
| Fixed Asset Turnover | - | - | - | - | 0.28x | 13.84x | 9.50x |
| Goodwill | 0 | 0 | 0 | 0 | 55.68M | 27.05M | 18.55M |
| Intangible Assets | 0 | 0 | 0 | 0 | 25.41M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 250.31K | 0 |
| Other Non-Current Assets | 15K | 199.93K | 0 | 38.62K | 383.54K | -250.31K | 225K |
| Total Assets | 6.08M▲ 0% | 4.81M▼ 20.9% | 3.08M▼ 35.9% | 26.31M▲ 752.9% | 87.52M▲ 232.6% | 28.18M▼ 67.8% | 24.93M▼ 11.5% |
| Asset Turnover | - | - | - | - | 0.00x | 0.09x | 0.03x |
| Asset Growth % | - | -20.87% | -35.9% | 752.93% | 232.64% | -67.8% | -11.55% |
| Total Current Liabilities | 75.76K | 68.67K | 1.64M | 3.92M | 17.19M | 18.29M | 9.14M |
| Accounts Payable | 18.38K | 68.67K | 582.61K | 1.5M | 5.3M | 3.79M | 1.76M |
| Days Payables Outstanding | 11.71K | 8.2K | 43.49K | 81.05K | 1.63K | 941.08 | 3.52K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 9.62M | 9.33M | 24.41K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 234.26K | 1.15M | 490.22K | 230.04K | 7.35M |
| Current Ratio | 79.98x | 66.94x | 1.88x | 6.69x | 0.34x | 0.05x | 0.66x |
| Quick Ratio | 79.98x | 66.94x | 1.88x | 6.69x | 0.32x | 0.05x | 0.65x |
| Cash Conversion Cycle | - | - | - | - | -583.26 | -911.23 | -3.08K |
| Total Non-Current Liabilities | 6.86K | 9.64K | 0 | 0 | 68.92M | 280.88K | 24.36K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 118.86K | 0 | 24.36K |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 74.29K | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 3.07M | 0 | 0 |
| Other Non-Current Liabilities | 6.86K | 9.64K | 0 | 0 | 65.66M | 280.88K | 0 |
| Total Liabilities | 82.62K | 78.31K | 1.64M | 3.92M | 86.11M | 18.57M | 9.16M |
| Total Debt | 0 | 0 | 0 | 0 | 9.89M | 9.45M | 48.77K |
| Net Debt | -6.05M | -4.31M | -1.93M | -25.75M | 5.33M | 8.8M | -5.17M |
| Debt / Equity | - | - | - | - | 7.04x | 0.98x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -54.72x | -41.44x | -8.45x |
| Total Equity | 6M▲ 0% | 4.73M▼ 21.1% | 1.45M▼ 69.4% | 22.39M▲ 1447.7% | 1.4M▼ 93.7% | 9.61M▲ 584.3% | 15.76M▲ 64.0% |
| Equity Growth % | - | -21.08% | -69.44% | 1447.65% | -93.73% | 584.28% | 64.03% |
| Book Value per Share | 527.49 | 416.28 | 127.21 | 1772.39 | 79.75 | 85.01 | 4.80 |
| Total Shareholders' Equity | 6M | 4.73M | 1.45M | 22.39M | -5.6M | 9.61M | 15.76M |
| Common Stock | 8 | 32 | 32 | 157 | 6 | 118 | 15 |
| Retained Earnings | -939.87K | -2.54M | -5.96M | -19.38M | -56.79M | -115.68M | -131.21M |
| Treasury Stock | 0 | 0 | 0 | -566.81K | -625.79K | -625.79K | -625.79K |
| Accumulated OCI | -8 | 0 | 0 | 0 | 2.38M | -2.72M | -231.03K |
| Minority Interest | 0 | 0 | 0 | 0 | 7.01M | 0 | 0 |
ONCO Cash Flow Statement
Onconetix, Inc. (ONCO) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -825.13K | -1.73M | -2.04M | -8.68M | -13.58M | -10.5M | -9.68M |
| Operating CF Margin % | - | - | - | - | -23229.31% | -415.82% | -1186.99% |
| Operating CF Growth % | - | -109.68% | -18.15% | -324.39% | -56.54% | 22.72% | 7.79% |
| Net Income | -821.91K | -1.6M | -3.42M | -13.42M | -37.41M | -58.69M | -14.03M |
| Depreciation & Amortization | 573 | 3.06K | 4.89K | 6.75K | 43.94K | 731.35K | 124.08K |
| Stock-Based Compensation | 3.27K | 334.84K | 130.14K | 1.97M | 329.76K | 438.65K | 74.27K |
| Deferred Taxes | 0 | -292.13K | 0 | 0 | -12.59K | -1.05M | 0 |
| Other Non-Cash Items | 0 | 292.13K | 23.44K | 202.51K | 21.84M | 49.61M | 6.58M |
| Working Capital Changes | -7.05K | -468.56K | 1.21M | 2.56M | 1.62M | -1.54M | -2.42M |
| Change in Receivables | -8.33K | -1.48K | -114.96K | 0 | -62.29K | 116.68K | -318.69K |
| Change in Inventory | 0 | 1.48K | 0 | 0 | -315.83K | -62.27K | -73.72K |
| Change in Payables | 18.38K | 50.29K | 336.71K | 1.09M | 3.37M | -1.48M | -1.09M |
| Cash from Investing | -4.5K | -11.79K | -1.92K | -32.66K | -8.65M | -28.47K | 0 |
| Capital Expenditures | -4.5K | -11.79K | -1.92K | -9.34K | -55.04K | -28.47K | 0 |
| CapEx % of Revenue | - | - | - | - | 94.15% | 1.13% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -23.33K | -8.59M | 0 | 0 |
| Cash from Financing | 6.88M | 0 | -334.19K | 32.53M | 1.04M | 6.74M | 14.45M |
| Debt Issued (Net) | -54.62K | 0 | 0 | 0 | -1M | 3.65M | -5.78M |
| Equity Issued (Net) | 6.93M | 0 | 0 | 34.3M | 2.24M | 3.48M | 20.23M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | -206.4K | -409.51K |
| Share Repurchases | 0 | 0 | 0 | -566.81K | -58.98K | -718 | 0 |
| Other Financing | 0 | 0 | -334.19K | -1.77M | -204.63K | -187.28K | 408.58K |
| Net Change in Cash | 6.05M▲ 0% | -1.74M▼ 128.8% | -2.38M▼ 36.6% | 23.82M▲ 1100.9% | -21.2M▼ 189.0% | -3.91M▲ 81.6% | 4.57M▲ 217.1% |
| Free Cash Flow | -829.63K▲ 0% | -1.74M▼ 110.0% | -2.05M▼ 17.5% | -8.68M▼ 324.4% | -13.64M▼ 57.0% | -10.52M▲ 22.8% | -9.68M▲ 8.0% |
| FCF Margin % | - | - | - | - | -23323.46% | -416.95% | -1186.99% |
| FCF Growth % | - | -109.97% | -17.47% | -324.45% | -57.01% | 22.82% | 8.04% |
| FCF per Share | -72.96 | -153.18 | -179.94 | -687.56 | -774.25 | -93.09 | -2.95 |
| FCF Conversion (FCF/Net Income) | 1.00x | 1.08x | 0.60x | 0.65x | 0.36x | 0.18x | 0.69x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 379.41K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ONCO Key Ratios
Onconetix, Inc. (ONCO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -13.7% | -29.81% | -110.59% | -112.61% | -314.47% | -1065.65% | -110.6% |
| Return on Invested Capital (ROIC) | - | -653.01% | - | - | -1603.32% | -336.95% | -32.81% |
| Gross Margin | - | - | - | - | -1927.93% | 41.8% | 77.62% |
| Net Margin | - | - | - | - | -63986.48% | -2325.21% | -1720.98% |
| Debt / Equity | - | - | - | - | 7.04x | 0.98x | 0.00x |
| Interest Coverage | - | - | - | - | -54.72x | -41.44x | -8.45x |
| FCF Conversion | 1.00x | 1.08x | 0.60x | 0.65x | 0.36x | 0.18x | 0.69x |
| Revenue Growth | - | - | - | - | - | 4217.31% | -67.7% |
ONCO Frequently Asked Questions
Onconetix, Inc. (ONCO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Onconetix, Inc. (ONCO) reported $0.8M in revenue for fiscal year 2025.
Onconetix, Inc. (ONCO) saw revenue decline by 67.7% over the past year.
Onconetix, Inc. (ONCO) reported a net loss of $14.0M for fiscal year 2025.
Dividend & Returns
Yes, Onconetix, Inc. (ONCO) pays a dividend with a yield of 27.73%. This makes it attractive for income-focused investors.
Onconetix, Inc. (ONCO) has a return on equity (ROE) of -110.6%. Negative ROE indicates the company is unprofitable.
Onconetix, Inc. (ONCO) had negative free cash flow of $9.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More ONCO
Onconetix, Inc. (ONCO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates